-
公开(公告)号：EP4019041A1
公开(公告)日：2022-06-29
申请号：EP21215762.2
申请日：2013-07-12
IPC分类号： A61K39/00
摘要： The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
-
公开(公告)号：EP4461308A2
公开(公告)日：2024-11-13
申请号：EP24202493.3
申请日：2013-07-12
IPC分类号： A61K39/00
摘要： The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
-
公开(公告)号：EP4036109A2
公开(公告)日：2022-08-03
申请号：EP21209515.2
申请日：2015-12-28
发明人： BEDOYA, Felipe , GHASSEMI, Saba , JUNE, Carl H. , LEVINE, Bruce L. , MELENHORST, Jan J. , MILONE, Michael C. , POWELL, Daniel J. Jr. , ZHENG, Zoe
IPC分类号： C07K14/725 , C12N5/00 , C12N5/0783 , A61K39/00
摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
-
公开(公告)号：EP3214091A1
公开(公告)日：2017-09-06
申请号：EP17153799.6
申请日：2011-12-09
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/585 , C07K14/075 , C07K14/525 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2317/622 , C07K2317/76 , C07K2317/80 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C12N7/00 , C12N15/85 , C12N15/861 , C12N2501/51 , C12N2501/515 , C12N2510/00 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
-
公开(公告)号：EP2872218A1
公开(公告)日：2015-05-20
申请号：EP13816421.5
申请日：2013-07-12
IPC分类号： A61P37/00
CPC分类号： A61K47/48561 , A61K47/6803 , A61K47/6849 , C07K16/2809 , C07K2317/77
摘要： The invention provides a method for inhibiting the depletion of healthy tissue during CAR T cell therapy comprising administering a drug-molecule conjugate comprising a drug and a molecule to a subject receiving CAR T cell therapy, wherein the molecule binds to a CAR expressed on the surface of a T cell. The invention relates to binding of the conjugate to the CAR resulting in internalization of the conjugate into the cell and drug-mediated death of the cell.
摘要翻译： 本发明提供了用于在CAR T细胞治疗期间抑制健康组织消耗的方法，其包括将包含药物和分子的药物 - 分子缀合物给予接受CAR T细胞疗法的受试者，其中所述分子结合表面上表达的CAR 的T细胞。 本发明涉及缀合物与CAR的结合，导致缀合物内化至细胞中并且药物介导的细胞死亡。
-
公开(公告)号：EP3305798A1
公开(公告)日：2018-04-11
申请号：EP17191702.4
申请日：2011-12-09
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/585 , C07K14/075 , C07K14/525 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2317/622 , C07K2317/76 , C07K2317/80 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C12N7/00 , C12N15/85 , C12N15/861 , C12N2501/51 , C12N2501/515 , C12N2510/00 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
-
公开(公告)号：EP4036109A3
公开(公告)日：2022-10-12
申请号：EP21209515.2
申请日：2015-12-28
发明人： BEDOYA, Felipe , GHASSEMI, Saba , JUNE, Carl H. , LEVINE, Bruce L. , MELENHORST, Jan J. , MILONE, Michael C. , POWELL, Daniel J. Jr. , ZHENG, Zoe
IPC分类号： C07K14/725 , C12N5/00 , C12N5/0783 , A61K39/00
摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
-
公开(公告)号：EP3660029A1
公开(公告)日：2020-06-03
申请号：EP19199404.5
申请日：2011-12-09
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
-
公开(公告)号：EP3214091B1
公开(公告)日：2018-10-03
申请号：EP17153799.6
申请日：2011-12-09
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/585 , C07K14/075 , C07K14/525 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2317/622 , C07K2317/76 , C07K2317/80 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C12N7/00 , C12N15/85 , C12N15/861 , C12N2501/51 , C12N2501/515 , C12N2510/00 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.027 秒)
